A Neil Woodford recovery stock I’d buy alongside AstraZeneca plc

Bolstering the risk of smaller-cap stocks by combining them with giants like AstraZeneca plc (LON: AZN) could be a winning strategy.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Ace investor Neil Woodford likes the look of IP commercialisation company Allied Minds (LSE: ALM). And so do I, now.

Mr Woodford holds it in his LF Woodford Equity Income Fund but hasn’t had a great deal of success with it so far. At 140p, the shares have lost 80% of their value since their peak in April 2015 — but he holds them in a well-diversified portfolio with a long-term vision.

On Monday, Allied Minds shareholders got some favourable news, with its SciFluor Life Sciences subsidiary announcing good results for its SF0166 candidate for the treatment of ‘wet’ age-related macular degeneration.

Headlines announced “improvements in vision along with significant decreases in central retinal thickness and fluid levels reported” in nine out of the 42 patients in the study, and “demonstrated safety with no drug-related serious adverse events.” It might sound obvious, but those two outcomes — it works, and it’s safe — can be remarkably hard to achieve.

Age-related macular degeneration can be seriously debilitating for its sufferers, so this has got to be seen as a positive step forSciFluor and for Allied Minds.

Wider technology

Looking at the bigger picture, Allied Minds — which is involved in technology and communication developments as well as life sciences — is starting to attract the funding it will need if it is to get as far as making a profit. A number of big investors took part in a funding round for subsidiary Federated Wireless in September which raised $42m.

There are no forecasts for profits on the horizon just yet, but today’s Allied Minds looks a significantly more attractive prospect after the decision to dump some of its subsidiaries earlier in the year. A bit speculative, but there could be great potential here.

Safety in size

Neil Woodford offsets risk by investing in established companies in similar sectors to his smaller investments — as well as the financial sector (including firms investing in technology), he holds a sizeable chunk of AstraZeneca (LSE: AZN).

And AstraZeneca had some welcome news the same day too, after the FDA in the US accepted a supplemental New Drug Application for the company’s cancer drug Tagrisso relating to the treatment of metastatic non-small cell lung cancer. The submission is based on the results of an earlier Phase III trial which showed significantly improved progression-free survival in patients with advanced metastases, and it comes after the European Medicines Agency had accepted a similar application.

It’s early days for the new development, but Tagrisso is already an approved drug for specific cancers in more than 60 countries, including the lucrative markets of the US, EU, China and Japan.

I’d buy now

Looking at the bigger picture for AstraZeneca, we’re still not back into forecast earnings growth territory yet, and the downturn that was driven by the expiry of some key patents a few years ago is lasting longer than many of us thought. 

But Q3 results make me think this year could turn out better than expected, with reported EPS for the first nine months looking flat overall (+3% at actual exchange rates, -4% at CER), with a fall in the underlying figure of between 4% and 7%.

Operating profit seems to be turning around nicely, and the predicted dividend looks reliable with a yield of 4.4%. I still see AstraZeneca as a dependable long-term investment.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

The Motley Fool UK has recommended AstraZeneca. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Illustration of flames over a black background
Investing Articles

2 red-hot UK growth stocks to consider buying in April

These two growth stocks are performing well, but can they continue to deliver for investors through 2024 and beyond?

Read more »

Charticle

Is JD Sports Fashion one of the FTSE 100’s best value stocks? Here’s what the charts say!

The JD Sports Fashion share price remains a wild ride during the first quarter. Could it be one of the…

Read more »

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »